Drug intelligence / Profile preview

BB-704

Development stage: Preclinical
Lead developer: BalinBac Therapeutics
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
Administration: Oral, Inhalation

Overview

BB-704 is a New Chemical Entity (NCE) drug conjugate being developed by BalinBac Therapeutics for the treatment of COVID-19. The molecule is engineered by linking two drug compounds via a chemical linker, a design intended to enhance antiviral efficacy against SARS-CoV-2. BB-704 is designed for delivery through both oral and inhalation routes, potentially allowing for flexible administration in different clinical settings. As of the current pipeline status, it is in early-stage development as an antiviral candidate.

Beyond the preview

Go deeper on BB-704.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BB-704.

Explore the full profile